Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Don't want to spend a fortune and break the bank on investing in growth stocks? The ones listed here all cost less than $100.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

JPMorgan analysts revised their outlook on Novo Nordisk (NYSE:NVO) stock, reducing the price target to DKK1,000 from DKK1,050. Despite the adjustment, they maintained an Overweight rating on the ...

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...